漢商集團(600774.SH):漢商醫療擬出資436萬元發起設立5家區域性醫療貿易公司
格隆匯12月1日丨漢商集團(600774.SH)公佈,公司控股孫公司武漢漢商醫療器械有限公司(以下簡稱“漢商醫療”)擬以現金人民幣總額436萬元與各合作方分別發起設立5家區域性醫療貿易公司。
湖南合資公司註冊資本200萬元,公司持股65%;河北合資公司註冊資本100萬元,公司持股51%;北京/內蒙合資公司註冊資本100萬元,公司持股51%;山東合資公司註冊資本100萬元,公司持股51%;福建合資公司註冊資本300萬元,公司持股51%。
通過設立上述合資公司,拓展醫療器械供應鏈管理業務在上述區域的影響力和市場佔有率,更好地賦能醫療器械產業鏈的發展,進一步做強公司大健康產業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.